Insights

Gathering insights about Process…

Similar companies to Process

Process Tech Stack

Process uses 8 technology products and services including SOLIDWORKS, Autodesk Inventor, ABAP, and more. Explore Process's tech stack below.

SOLIDWORKS
Cad & Graphics
Autodesk Inventor
Cad & Graphics
ABAP
Enterprise
Dell
IT Infrastructure
Exhibit.js
Javascript Graphics
Windows Server
Operating Systems
Java
Programming Languages
ZURB Foundation
UI Frameworks

Media & News

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.
Feb 07, 2025 | www.globenewswire.com
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the closing of its previously announced “reasonable best efforts” public offering with participation from the Company's Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase up to 4,025,336 shares of common stock at a combined purchase price per share (and accompanying warrants) of $0.615 for the institutional investors and $0.7975 for the Company's Chief Executive Officer and certain board members. The closing occurred on January 29, 2025.
Jan 30, 2025 | www.globenewswire.com
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pricing of its “reasonable best efforts” public offering with participation from the Company's Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase up to 4,025,336 shares of common stock at a combined purchase price per share (and accompanying warrants) of $0.615 for the institutional investors and $0.7975 for the Company's Chief Executive Officer and certain board members.
Jan 27, 2025 | www.globenewswire.com
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer.
Oct 02, 2024 | www.globenewswire.com
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:
Sep 03, 2024 | www.globenewswire.com
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap).
Jul 30, 2024 | investorplace.com
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exposure was greater and fluoro-beta-alanine (FBAL) exposure was lower with a better or similar side-effect profile than monotherapy capecitabine HANOVER, MD., June 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial which defined the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose Range (RP2DR) for Next Generation Capecitabine (NGC-Cap) administered to patients with Stage III or IV gastrointestinal tract (GI) cancer.
Jun 11, 2024 | www.globenewswire.com

Process's Email Address Formats

Process uses at least 1 format(s):

Process Email Formats	Example	Percentage
F.Last@schenckprocess.com	J.Doe@schenckprocess.com	84%
First.Last@schenckprocess.com	John.Doe@schenckprocess.com	8%
FirstLast@schenckprocess.com	JohnDoe@schenckprocess.com	6%
FLast@schenckprocess.com	JDoe@schenckprocess.com	2%

Frequently Asked Questions

Where is Process's headquarters located?

Process's main headquarters is located at United States. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Process's stock symbol?

Process is a publicly traded company; the company's stock symbol is PCSA.

What is Process's official website and social media links?

Process's official website is schenckprocess.com and has social profiles on LinkedIn.

What is Process's SIC code NAICS code?

Process's SIC code is 3823 - Industrial Instruments for Measurement, Display, and Control of Process Variables; and Related Products NAICS code is 5112 - Software Publishers.

How many employees does Process have currently?

As of March 2025, Process has approximately 10K employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: D. J.Chief Executive Officer: M. P.Artworker And Digital Developer And Co-Owner: C. A.. Explore Process's employee directory with LeadIQ.

What industry does Process belong to?

Process operates in the Software Development industry.

What technology does Process use?

Process's tech stack includes SOLIDWORKSAutodesk InventorABAPDellExhibit.jsWindows ServerJavaZURB Foundation.

What is Process's email format?

Process's email format typically follows the pattern of . Find more Process email formats with LeadIQ.

Process

Software DevelopmentUnited States10001+ Employees

Learn about working at Process. Join LinkedIn today for free. See who you know at Process, leverage your professional network, and get hired.

Company Overview

Headquarters: United States
Website: schenckprocess.com
SIC Code: 3823 - Industrial Instruments for Measurement, Display, and Control of Process Variables; and Related Products
Stock Symbol: PCSA
NAICS Code: 5112 - Software Publishers
Employees: 10001+

Media & News

Funding & Financials

$10M$50M
Process's revenue is in the range of $10M$50M

Funding & Financials

$10M$50M
Process's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Process

Freemavens

Thinkhouse

Process Tech Stack

Media & News

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Process's Email Address Formats

Frequently Asked Questions

Where is Process's headquarters located?

What is Process's stock symbol?

What is Process's official website and social media links?

What is Process's SIC code NAICS code?

How many employees does Process have currently?

What industry does Process belong to?

What technology does Process use?

What is Process's email format?

Process

Company Overview

Media & News

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?